
Product Data Sheet

Product Name: Losartan D4
 Cat. No.: GC36480

Chemical Properties

Cas. No. 1030937-27-9

SMILES OCC1=C(Cl)N=C(CCCC)N1CC2=C([2H])C([2H])=C(C3=CC=CC=C3C4=NNN=N4)C([2H])=C2[2H]

Formula C₂₂H₁₉D₄ClN₆O

M.Wt 426.94

Solubility DMSO: 100 mM, Ethanol: 100 mM

Storage Store at -20°C

General For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Evaluation sample solution: ship with blue ice. All other available size: ship with RT, or blue ice Condition upon request.

Structure

Background

Losartan-d₄ is intended for use as an internal standard for the quantification of losartan (potassium salt) by GC- or LC-MS. Losartan is an antagonist of the angiotensin (AT) II receptor subtype AT₁ with a K_i value of 5-20 nM.¹ It has an attenuating effect on vein graft atherosclerosis in rabbits and effectively reduces arterial blood pressure in rats.^{2,3} Formulations containing losartan have been used to control hypertension while protecting renal function.⁴

1. Ji, H., Leung, M., Zhang, Y., et al. Differential structural requirements for specific binding of nonpeptide and peptide antagonists to the AT₁ angiotensin receptor. Identification of amino acid residues that determine binding of the antihypertensive drug losartan. *J. Biol. Chem.* 269(24):16533-16536 (1994)
 2. Ge, J., Huang, D., Liang, C., et al. Upregulation of lectinlike oxidized low-density lipoprotein receptor-1 expression contributes to the vein graft atherosclerosis: Modulation by losartan. *Atherosclerosis* 177(2):263-268 (2004)
 3. Xavier, F.E., Rossoni, L.V., Alonso, M.J., et al. Ouabain-induced hypertension alters the participation of endothelial factors in α -adrenergic responses differently in rat resistance and conductance mesenteric arteries. *Br. J. Pharmacol.* 143(1):215-225 (2004)
 4. Caruso, D., D'Avino, M., Acampora, C., et al. Effects of losartan and chlorthalidone on blood pressure and renal vascular resistance index in non-diabetic patients with essential hypertension and normal renal functions. *J. Cardiovasc. Pharmacol.* 44(5):520-524 (2004)

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA